Search research articles
Contact Us
Filters
Showing results (161-170 of 238) with videos related to
Page
of 24
Sort By:
Liver International : Official Journal of the International Association for the Study of the Liver
|
August 20, 2022
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
Mathew Vithayathil, Antonio D'Alessio, Claudia A M Fulgenzi, et al.
Hepatology International
|
April 3, 2023
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
Mathew Vithayathil, Antonio D'Alessio, Claudia Angela Maria Fulgenzi, et al.
Journal of Hepatology
|
April 3, 2022
T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma
Maryam Barsch, Henrike Salié, Alexandra Emilia Schlaak, et al.
Thoracic Cancer
|
December 23, 2021
Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy
Giuseppe L Banna, Marcello Tiseo, Diego L Cortinovis, et al.
Liver Cancer
|
December 24, 2021
Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma
Petros Fessas, Muntaha Naeem, Matthias Pinter, et al.
JHEP Reports : Innovation in Hepatology
|
December 1, 2025
Lenvatinib <i>vs.</i> sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study
Pasquale Lombardi, Jung Sun Kim, Giulia F Manfredi, et al.
Clinical Genitourinary Cancer
|
January 11, 2025
Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma
Rafee Talukder, Dimitra Rafailia Bakaloudi, Dimitrios Makrakis, et al.
Journal for Immunotherapy of Cancer
|
February 17, 2022
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations
Alessio Cortellini, Biagio Ricciuti, Victor R Vaz, et al.
Hepatology (Baltimore, Md.)
|
November 8, 2019
Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach
Guohong Han, Sarah Berhane, Hidenori Toyoda, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
December 28, 2022
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study
Thomas Talbot, Antonio D'Alessio, Matthias Pinter, et al.
Page
of 24
Search research articles
Search
Showing results (161-170 of 238) with videos related to
Sort By:
Page
of 24
Liver International : Official Journal of the International Association for the Study of the Liver
|
August 20, 2022
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
Mathew Vithayathil, Antonio D'Alessio, Claudia A M Fulgenzi, et al.
Hepatology International
|
April 3, 2023
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
Mathew Vithayathil, Antonio D'Alessio, Claudia Angela Maria Fulgenzi, et al.
Journal of Hepatology
|
April 3, 2022
T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma
Maryam Barsch, Henrike Salié, Alexandra Emilia Schlaak, et al.
Thoracic Cancer
|
December 23, 2021
Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy
Giuseppe L Banna, Marcello Tiseo, Diego L Cortinovis, et al.
Liver Cancer
|
December 24, 2021
Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma
Petros Fessas, Muntaha Naeem, Matthias Pinter, et al.
JHEP Reports : Innovation in Hepatology
|
December 1, 2025
Lenvatinib <i>vs.</i> sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study
Pasquale Lombardi, Jung Sun Kim, Giulia F Manfredi, et al.
Clinical Genitourinary Cancer
|
January 11, 2025
Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma
Rafee Talukder, Dimitra Rafailia Bakaloudi, Dimitrios Makrakis, et al.
Journal for Immunotherapy of Cancer
|
February 17, 2022
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations
Alessio Cortellini, Biagio Ricciuti, Victor R Vaz, et al.
Hepatology (Baltimore, Md.)
|
November 8, 2019
Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach
Guohong Han, Sarah Berhane, Hidenori Toyoda, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
December 28, 2022
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study
Thomas Talbot, Antonio D'Alessio, Matthias Pinter, et al.
Page
of 24